<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974350</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN803-006-0006</org_study_id>
    <nct_id>NCT00974350</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of SABER™-Bupivacaine for Pain Following Hernia Repair</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Pharmacodynamic and Pharmacokinetic Dose Response Study of SABER™-Bupivacaine Instilled Into the Wound in Patients Undergoing Open Inguinal Hernia Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study testing SABER™-Bupivacaine (an experimental pain-relieving
      medication). SABER™-Bupivacaine is designed to continuously deliver bupivacaine, a common
      local anesthetic, for a few days in order to treat local post-surgical pain. This study is
      testing SABER™-Bupivacaine in people having surgery to repair a hernia.

      The purpose of the study is to measure and compare the safety (side effects), tolerability
      (ability to tolerate), and efficacy (how well it works) of two different volumes of
      SABER™-Bupivacaine with SABER™-Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>0 to 3 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients using supplemental opioids</measure>
    <time_frame>0 to 14 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>0 to 2 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>1 to 5 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental opioid use</measure>
    <time_frame>0 to 14 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean function activities</measure>
    <time_frame>1 to 5 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Hernia</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Group 1: SABER™-Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mL SABER™-Bupivacaine /Once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: SABER™-Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 mL SABER™-Bupivacaine /Once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: SABER™-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2.5 mL or 5.0 mL SABER™-Placebo/Once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER™-Bupivacaine</intervention_name>
    <description>Injectable Extended Release Solution; 2.5 mL SABER™-Bupivacaine/Once</description>
    <arm_group_label>Group 1: SABER™-Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER™-Bupivacaine</intervention_name>
    <description>Injectable Extended Release Solution; 5.0 mL SABER™-Bupivacaine/Once</description>
    <arm_group_label>Group 2: SABER™-Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER™-Placebo</intervention_name>
    <description>Injectable Solution; 2.5 or 5.0 mL SABER™-Placebo/Once</description>
    <arm_group_label>Group 3: SABER™-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 to 65 years of age, scheduled for hernia repair surgery

          -  Patients must be in good health prior to study participation

          -  Patients must have blood pressure within normal range or with Stage 1 high blood
             pressure

          -  Male and female patients must agree to use medically acceptable method of
             contraception throughout the entire trial period and for 1 week after the trial is
             completed

          -  Patients must refrain from strenuous activities and avoid changes to prescribed
             exercise levels throughout the course of the trial

          -  Ability to read, understand, communicate, and voluntarily sign the informed consent
             form prior to any trial specific procedures

        Exclusion Criteria:

          -  Patients with previous abdominal surgery scar tissue

          -  Patients with clinically significant abnormalities of any body system unrelated to the
             disease under study

          -  Connective tissue disorders

          -  Patients who are pregnant or lactating

          -  Current or regular use of analgesic medication for other indications

          -  Patients with current or regular use of antidepressants or monoamine oxidase
             inhibitors at screening

          -  Use of any drugs or medication that may interfere with the study and its results

          -  Patients with known hypersensitivity to the study drugs or their components

          -  Patients with known or suspected alcohol abuse or illicit drug use

          -  Participation in another clinical trial at the same time or within 30 days of this
             trial

          -  Patient is unwilling to comply with the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitri Lissin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Durect</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunnybank</city>
        <state>Queensland</state>
        <zip>4109</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Lincoln</city>
        <state>South Australia</state>
        <zip>5606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <results_reference>
    <citation>Hadj A, Hadj A, Hadj A, Rosenfeldt F, Nicholson D, Moodie J, Turner R, Watts R, Fletcher I, Abrouk N, Lissin D. Safety and efficacy of extended-release bupivacaine local anaesthetic in open hernia repair: a randomized controlled trial. ANZ J Surg. 2012 Apr;82(4):251-7. doi: 10.1111/j.1445-2197.2011.05754.x. Epub 2011 Jun 24.</citation>
    <PMID>22510183</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <disposition_first_submitted>December 21, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>December 21, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 23, 2009</disposition_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dmitri Lissin, MD, Sr. Director Clinical Research</name_title>
    <organization>Durect Corporation</organization>
  </responsible_party>
  <keyword>Post-operative pain</keyword>
  <keyword>hernia surgery</keyword>
  <keyword>opioid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

